# Kinaset Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kinaset-therapeutics

- Industry: Biotechnology
- Headquarters: Medfield, US
- Website: www.kinasettherapeutics.com
- Total disclosed funding: $143M
- Latest round: Series B (Jan 10, 2026)
- Investors on record: 11

## About

Based in the US, Kinaset Therapeutics, Inc. is a biotechnology company focused on developing innovative inhaled therapeutics aimed at treating severe asthma through its lead product, KN-002, which targets underlying inflammation effectively.Kinaset Therapeutics, Inc. was founded in 2020 by CEO Robert Clarke, COO Roger Heerman, and CDO Frazer Morgan in Massachusetts, US. The company specializes in inhaled therapeutics for severe asthma patients. In January 2026, Kinaset Therapeutics, Inc. raised USD 103 million in Series B funding co-led by RA Capital Management and Forge Life Science Partners, with participation from EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, and Sixty Degree Capital. Atlas Venture, 5AM Ventures, and Gimv also participated in the round.  Kinaset Therapeutics focuses on developing innovative inhaled therapeutics for patients suffering from severe asthma, specifically through its lead product, KN-002. This product is designed to treat all patients with severe asthma, targeting the underlying inflammation regardless of its cause. KN-002 utilizes a novel, non-invasive anti-inflammatory approach that allows for the direct delivery of medication to the lungs, minimizing systemic exposure and enhancing the therapeutic impact at the site of need. The primary end users of this product are individuals diagnosed with severe asthma, who are seeking more effective treatment options to manage their condition. Kinaset's products are primarily aimed at markets in North America and Europe, where there is a significant demand for advanced therapeutic alternatives in respiratory disease management.Kinaset Therapeutics operates within a structured revenue model that includes partnerships with healthcare providers and distributors focused on respiratory therapeutics. The company’s transactions involve direct sales to healthcare facilities and potentially retail pharmacies, where KN-002 is made available to patients through prescription. While specific pricing for KN-002 and associated services are not disclosed, the revenue generation is fundamentally linked to the successful adoption and sales of this flagship product in the healthcare marketplace. The firm’s revenue framework is supported by the increasing need for effective asthma treatments, which underscores the growth potential in this sector. In January 2026, Kinaset Therapeutics, Inc. raised USD 103 million in series B funding co-led by new investors RA Capital Management and Forge Life Science Partners, with participation from other new investors EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, and Sixty Degree Capital. Returning investors Atlas Venture, 5AM Ventures, and Gimv also participated in the round. The company will use the January 2026 funding to support its growth and further development of its inhaled maintenance therapies services.

## Funding rounds

- Series B, Jan 10, 2026, $103M — Schroders Capital, Atlas Venture, EQT Life Sciences, Gimv, 5AM Ventures, Vivo Capital, Willett Advisors, Pictet Alternative Advisors, RA Capital Management, Sixty Degree Capital, Forge Life Science Partners
- Series A, Nov 30, 2020, $40M — Atlas Venture, Gimv, 5AM Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Willett Advisors — Series B
- Pictet Alternative Advisors (https://capitalatlas.ai/funds/pictet-alternative-advisors) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series B
- Forge Life Science Partners (https://capitalatlas.ai/funds/forge-life-science-partners) — Series B